Dr. Curtis J. Mello, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- Boston University School of Medicine (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 757
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: Boston University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
MA license 79856 · RI license MD07880
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- The Miriam Hospital Providence, RI
- Rhode Island Hospital Providence, RI
- Southcoast Hospitals Group Fall River, MA
- Newport Hospital Newport, RI
Medical groups
- Pulmonary and Sleep Medicine Associates Inc (5 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 757
- Services billed
- 2,472
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 1,088 | 691 |
| Established patient office or other outpatient visit, 30-39 minutes | 403 | 239 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 201 | 198 |
| Test to examine how well the lungs exchange gases | 189 | 189 |
| New patient office or other outpatient visit, 45-59 minutes | 167 | 167 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | 167 | 59 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 154 | 154 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 10 minutes | 145 | 53 |
| Test to determine lung volumes using gas dilution or washout | 142 | 137 |
| New patient office or other outpatient visit, 30-44 minutes | 134 | 134 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Montelukast Sodium Other prescribers in North Dartmouth, MA | 661 |
| Prednisone Other prescribers in North Dartmouth, MA | 650 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in North Dartmouth, MA | 548 |
| Atorvastatin Calcium Other prescribers in North Dartmouth, MA | 406 |
| Trazodone Hcl Other prescribers in North Dartmouth, MA | 382 |
| Amlodipine Besylate Other prescribers in North Dartmouth, MA | 365 |
| Levothyroxine Sodium Other prescribers in North Dartmouth, MA | 333 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in North Dartmouth, MA | 326 |
| Gabapentin Other prescribers in North Dartmouth, MA | 274 |
| Simvastatin Other prescribers in North Dartmouth, MA | 258 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 29 payments worth $5,952 in total to this clinician.
| Viatris Specialty LLC | $3,037 |
|---|---|
| Chiesi USA, Inc. | $2,377 |
| AstraZeneca Pharmaceuticals LP | $221 |
| GlaxoSmithKline, LLC. | $183 |
| Amgen Inc. | $53.73 |
| Verona Pharma, Inc. | $34.09 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $25.47 |
| 3b Medical, Inc. | $20.64 |
| Compensation for services other than consulting (speaking, faculty) | $3,018 |
|---|---|
| Travel and Lodging | $2,288 |
| Food and Beverage | $612 |
| Education | $34.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Chiesi USA, Inc. Jan 24, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $2,288 |
| Viatris Specialty LLC Sep 9, 2025 | Compensation for services other than consulting (speaking, faculty) YUPELRI · Anticholinergics, Inhaled | $2,012 |
| Viatris Specialty LLC Sep 25, 2025 | Compensation for services other than consulting (speaking, faculty) YUPELRI · Anticholinergics, Inhaled | $1,006 |
| Amgen Inc. Aug 29, 2025 | Education in-kind | $34.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 14 industry-funded studies in 2025, from 7 companies. The companies reported $128,578 in research payments for these studies, mostly to the institutions running them.
- A phase 3, 52-week, randomized, double-blind, placebo-controlled, para
GlaxoSmithKline, LLC. - A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in…
Teva Pharmaceuticals USA, Inc. - Randomized Double blind Placebo controlled Parallel Group Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary D…
AstraZeneca Pharmaceuticals LP - A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
Boehringer Ingelheim Pharmaceuticals, Inc. - Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
United Therapeutics Corporation · Recruiting · NCT05943535 - A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chron…
AstraZeneca Pharmaceuticals LP - An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON)
Boehringer Ingelheim Pharmaceuticals, Inc. - A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obs…
AstraZeneca Pharmaceuticals LP - A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Eli Lilly and Company · Completed · NCT04255433 - A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF)
Boehringer Ingelheim Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.